A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8⁺ T cells.

ABSTRACT: Strategies to increase intratumoral concentrations of an anticancer agent are desirable to optimize its therapeutic potential when said agent is efficacious primarily within a tumor but also have significant systemic side effects. Here, we generate a bifunctional protein by fusing interleukin-10 (IL-10) to a colony-stimulating factor-1 receptor (CSF-1R)-blocking antibody. The fusion protein demonstrates significant antitumor activity in multiple cancer models, especially head and neck cancer. Moreover, this bifunctional protein not only leads to the anticipated reduction in tumor-associated macrophages but also triggers proliferation, activation, and metabolic reprogramming of CD8⁺ T cells. Furthermore, it extends the clonotype diversity of tumor-infiltrated T cells and shifts t

SUBMITTER: Chang YW 

PROVIDER: S-EPMC10439276 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature